ATH 6.06% 3.1¢ alterity therapeutics limited

powerful messages

  1. 22,691 Posts.
    PBT has a number of very important developments to come:
    1. To start in 2004: Stage I of the trial of PBT-2, a compound to treat Alzheimers:

    "PBT-1 is the initial drug compound which has established proof of concept of Prana's approach and advanced to successful Phase II clinical trials. Prana’s proof of concept outlines the role of metal protein attenuating compounds in targeting the interaction between beta amyloid and oxidised metals in the brains of Alzheimer’s Disease patients.

    "This step shows that Prana is bolstering its strong position to be the company behind an effective treatment for the highly debilitating Alzheimer's Disease,” said Dr Ross Murdoch, Prana’s Chief Operating Officer. "This is a major milestone and is the result of an impressive in house medicinal chemistry team effort."

    “We have designed compounds that are superior to PBT-1. PBT-2 is a small molecular weight chemical entity that demonstrates a significant improvement on PBT-1. PBT-2 has characteristics appropriate for oral bioavailability and blood brain barrier permeability. PBT-2 exceeds PBT-1 in both pre-clinical in-vitro and in vivo-testing.

    2. Parkinson's disease:

    Date: 28/3/2003:

    Extract: "The article postulates that the presence of excess iron in the brain is associated with, and may aggravate, oxidative stress. “Reduction in reactive iron by either genetic or pharmacological means,” [through the use of clioquinol, an example of a Prana MPAC class molecule], “was found to be well tolerated in animals … and to result in protection against the toxin, suggesting that iron chelation may be an effective therapy for prevention and treatment of (Parkinson’s) disease.”

    3. Collaboration with PRR to develop a vaccine for Alzheimer' disease.

    Australian biotechnology companies Prima Biomed (ASX:PRR) and Prana Biotechnology
    (ASX:PBT) have formed a collaboration with the Austin Research Institute and the University of Melbourne to develop the world's first vaccine for Alzheimer's Disease.

    Prana's scientists have won scientific acceptance of their findings about the link between metals in the brain and the development of Alzheimer's Disease and have conducted successful human trials testing metal protein attenuating compounds (MPAC) to treat the disease.

    The collaboration will enable Prima Biomed's highly encouraging new Panvax vaccine technology, called DCtag, to be used in conjunction with these compounds to assist the body’s immune system to recognise the protein or peptide extracts associated with Alzheimer's

watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Mkt cap ! $64.60M
Open High Low Value Volume
3.1¢ 3.1¢ 3.1¢ $99.68K 3.215M

Buyers (Bids)

No. Vol. Price($)
31 3794017 3.1¢

Sellers (Offers)

Price($) Vol. No.
3.2¢ 468742 2
View Market Depth
Last trade - 16.10pm 13/04/2021 (20 minute delay) ?
-0.002 ( 3.03 %)
Open High Low Volume
3.1¢ 3.2¢ 3.1¢ 1623922
Last updated 15.59pm 13/04/2021 (live) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.